| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
N/A |
| Shares
Out: |
61,150,000 |
| Market
Cap: |
6.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$113.49 - $145.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
12,000 |
12,000 |
12,000 |
12,000 |
| Total Buy Value |
$1,435,800 |
$1,435,800 |
$1,435,800 |
$1,435,800 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
3,704 |
4,538 |
27,327 |
202,315 |
| Total Sell Value |
$438,449 |
$537,921 |
$3,641,323 |
$29,586,917 |
| Total People Sold |
1 |
3 |
13 |
19 |
| Total Sell Transactions |
2 |
4 |
21 |
79 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Enright Patrick G |
Director |
– • – |
2023-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,075 |
22,187 |
|
- |
|
| Mcsharry Heather Ann |
Director |
– • – |
2023-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,075 |
18,122 |
|
- |
|
| Mulligan Seamus |
Director |
– • – |
2023-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,075 |
1,172,375 |
|
- |
|
| Riedel Norbert G |
Director |
– • – |
2023-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,075 |
14,946 |
|
- |
|
| Gray Peter |
Director |
– • – |
2023-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,075 |
17,309 |
|
- |
|
| Smith Mark Douglas |
Director |
– • – |
2023-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,075 |
8,546 |
|
- |
|
| Winningham Rick E |
Director |
– • – |
2023-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,075 |
11,685 |
|
- |
|
| Okeefe Kenneth W |
Director |
– • – |
2023-08-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,075 |
25,964 |
|
- |
|
| Patil Neena M |
EVP & Chief Legal Officer |
• – – |
2023-08-07 |
4 |
D |
$131.51 |
$182,799 |
D/D |
(1,390) |
31,436 |
|
- |
|
| Mulligan Seamus |
Director |
– • – |
2023-06-08 |
4 |
OE |
$81.76 |
$367,920 |
D/D |
4,500 |
1,169,300 |
|
- |
|
| Carr Patricia |
SVP, Chief Accounting Officer |
• – – |
2023-06-07 |
4 |
S |
$127.92 |
$16,117 |
D/D |
(126) |
6,286 |
|
- |
|
| Sablich Kim |
EVP, GM of U.S. |
• – – |
2023-06-05 |
4 |
D |
$129.73 |
$270,098 |
D/D |
(2,082) |
28,478 |
|
- |
|
| Iannone Robert |
EVP, Global Head of Research a |
• – – |
2023-06-05 |
4 |
D |
$129.73 |
$170,076 |
D/D |
(1,311) |
45,315 |
|
- |
|
| Patil Neena M |
EVP & Chief Legal Officer |
• – – |
2023-06-01 |
4 |
S |
$127.98 |
$204,763 |
D/D |
(1,600) |
32,826 |
|
- |
|
| Gala Renee D |
EVP & Chief Financial Officer |
• – – |
2023-05-18 |
4 |
S |
$131.75 |
$790,474 |
D/D |
(6,000) |
35,978 |
|
- |
|
| Gala Renee D |
EVP & Chief Financial Officer |
• – – |
2023-04-05 |
4 |
D |
$145.78 |
$263,424 |
D/D |
(1,807) |
41,978 |
|
- |
|
| Carr Patricia |
SVP, Chief Accounting Officer |
• – – |
2023-03-15 |
4 |
AS |
$133.22 |
$136,284 |
D/D |
(1,023) |
6,286 |
|
- |
|
| Sablich Kim |
EVP, GM of U.S., Commercial Ma |
• – – |
2023-03-08 |
4 |
AS |
$139.42 |
$421,043 |
D/D |
(3,013) |
30,560 |
|
- |
|
| Okeefe Kenneth W |
Director |
– • – |
2023-03-07 |
4 |
S |
$138.39 |
$372,267 |
D/D |
(2,690) |
22,889 |
|
- |
|
| Okeefe Kenneth W |
Director |
– • – |
2023-03-07 |
4 |
OE |
$81.76 |
$367,920 |
D/D |
4,500 |
25,579 |
|
- |
|
| Larkin Finbar |
SVP, Technical Operations |
• – – |
2023-03-07 |
4 |
S |
$140.76 |
$292,081 |
D/D |
(2,075) |
21,779 |
|
- |
|
| Larkin Finbar |
SVP, Technical Operations |
• – – |
2023-03-06 |
4 |
S |
$143.92 |
$245,526 |
D/D |
(1,706) |
23,854 |
|
- |
|
| Larkin Finbar |
SVP, Technical Operations |
• – – |
2023-03-06 |
4 |
OE |
$58.72 |
$100,176 |
D/D |
1,706 |
25,560 |
|
- |
|
| Carr Patricia |
SVP, Chief Accounting Officer |
• – – |
2023-03-05 |
4 |
S |
$140.76 |
$161,594 |
D/D |
(1,148) |
7,309 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2023-03-05 |
4 |
D |
$142.78 |
$3,124,312 |
D/D |
(21,882) |
387,584 |
|
- |
|
881 Records found
|
|
Page 3 of 36 |
|
|
0.37 (0.34%) 
